Single-Dose CRISPR Gene Therapy Safely Lowers LDL Cholesterol by 52.5% After One Year in Phase 1 Trial

For millions of people managing stubborn cholesterol, the daily routine of swallowing statins or the bi-weekly schedule of administering injectable medications represents a lifelong, unrelenting commitment to cardiovascular health. But the treatment landscape is steadily shifting toward a future where managing dangerous lipid disorders might require just a single, permanent intervention. In a landmark phase 1a clinical trial, a one-time intravenous infusion of an investigational CRISPR-Cas9 gene-editing therapy called CTX310 safely and durably lowered LDL cholesterol by 52.5% and triglycerides by 47.8% after one full year. By proving that a single treatment can yield lasting biological changes without immediate severe side effects, researchers are opening a new frontier in preventive cardiology that could eventually render daily cholesterol pills obsolete for high-risk patients.[1][5]

The data, which was presented to a packed audience at the 2026 European Society of Cardiology Congress in Munich and published simultaneously in the New England Journal of Medicine, marks a critical milestone for the field of in vivo gene editing. The trial tracked 15 adult participants with medication-resistant lipid disorders, including severe familial hypercholesterolemia, who had exhausted standard maximum-tolerated therapies. By demonstrating that a single dose can produce deep, sustained lipid lowering without triggering severe immune responses or liver damage, the findings suggest that the concept of a "one-and-done" treatment for cardiovascular disease is rapidly moving from an abstract scientific theory to a tangible clinical reality.[1][2][3][4][5]

The therapy, developed by the biotechnology company CRISPR Therapeutics, works by fundamentally altering how the human liver processes and clears fats from the bloodstream. Delivered via tiny, specialized lipid nanoparticles that act as microscopic delivery vehicles, the CRISPR-Cas9 mechanism functions as a pair of highly precise molecular scissors. Once inside the liver cells, it specifically targets and switches off a gene known as ANGPTL3. This specific gene naturally regulates lipid metabolism, and its suppression allows the body to clear atherogenic lipoproteins—the harmful fats that build up in arteries and cause heart attacks—much more efficiently than it normally would.[2][3]

The biological inspiration for this cutting-edge approach actually comes from observing natural human genetics. Researchers have long known that individuals born with natural loss-of-function mutations in the ANGPTL3 gene tend to have lifelong low cholesterol and a significantly reduced lifetime risk of developing atherosclerotic cardiovascular disease, all without experiencing any apparent harmful health effects from the mutation. By artificially replicating this exact genetic advantage through targeted CRISPR editing, CTX310 aims to provide a durable biological fix at the DNA level, rather than relying on the temporary chemical suppression offered by conventional drugs that wash out of the system if a dose is missed.[3][4][5]

The durability of the lipid-lowering effect was the primary and most urgent question this one-year follow-up study sought to answer. Because the human liver is a highly regenerative organ that constantly recycles and replaces its cells, researchers needed to know if the genetic edit would eventually wash out or be diluted over time. At the highest dose tested in the trial (0.8 mg/kg), the therapy achieved an impressive average 79% reduction in circulating ANGPTL3 protein, and those reductions persisted robustly through the full 12 months, confirming that the edit is stable and that the liver continues to produce the modified cells.[2][4][5]

For patients who might eventually consider making the leap from conventional daily pills to permanent gene editing, safety is naturally the paramount concern. The one-year follow-up data offers substantial reassurance on this front: researchers reported absolutely no serious adverse events related to the therapy, no ongoing liver-function abnormalities, and only mild, temporary infusion-related reactions such as transient back pain or mild nausea that resolved quickly. The complete lack of dose-limiting toxicities across all cohorts is a highly encouraging signal for the platform's overall safety profile, suggesting the lipid nanoparticles are delivering the payload without causing systemic inflammation.[1][2][3]

However, the medical community and regulatory agencies remain appropriately cautious about the long-term implications of the technology. Because CRISPR permanently alters a patient's fundamental DNA, the U.S. Food and Drug Administration requires a mandatory 15-year safety monitoring period for all patients receiving any gene-editing therapies. This extensive follow-up is designed to ensure that no unintended off-target genetic consequences, such as an increased risk of cellular mutations or unexpected metabolic shifts, emerge over the course of a decade or more. While the initial safety data is remarkably clean, the true long-term safety of permanently disabling a liver gene in a broad population will take years of careful observation to fully establish.[5][6]

The practical promise of this approach lies in solving the pervasive "adherence gap" in preventive cardiology. Even the most highly effective cholesterol medications, such as high-intensity statins, only work if patients actually take them consistently, and real-world adherence to daily preventive pills notoriously drops over time due to side effects, cost, or simple pill fatigue. A one-time infusion that permanently lowers dangerous circulating lipids could entirely eliminate the risk of missed doses, particularly for high-risk patients with severe familial hypercholesterolemia who struggle to reach safe cardiovascular targets even when strictly adhering to maximum conventional therapies.[3][4][6]

While these phase 1 results are highly encouraging for the future of cardiology, CTX310 is not yet available at your local clinic and remains strictly experimental. The therapy is now advancing into phase 1b clinical trials, which will evaluate a fixed dose specifically in patients suffering from severe hypertriglyceridemia, with further clinical updates expected in the second half of 2026. Until larger, late-stage, multi-center trials confirm these long-term benefits and safety profiles across thousands of diverse patients, individuals managing high cholesterol should continue taking their prescribed statins, PCSK9 inhibitors, or other evidence-based lipid-lowering regimens without interruption.[2][3][6]

The early success of CTX310 also signals a much broader and highly anticipated shift in cardiovascular medicine as a whole. Researchers and pharmaceutical developers are increasingly looking at in vivo gene editing not just as a niche tool for rare genetic diseases, but as a viable weapon against widespread public health challenges. The same underlying technology is already being adapted for therapies targeting angiotensinogen to treat refractory hypertension, and LPA to address elevated lipoprotein(a). If the safety profile continues to hold up under rigorous testing, the era of treating chronic cardiovascular risk factors at their genetic root may finally be arriving.[2][4][6]